Targeting Shp2 has disappointed, but Novartis shows that it might still make an impression in directly hitting Kras.
The dour biotech market sees little to be impressed about in updates from Bicycle, Rubius, C4 and Zentalis, though well-received data gives Affimed a boost.
But it’s still far too early to tell whether combining Car-T with an mRNA vaccine might improve response durability.
An academic-sponsored trial gives Affimed’s NK cell engaging approach a huge endorsement.
Mavacamten prevails again, but the big question for Bristol is the commercial opportunity.